Pharmacokinetics, safety, and efficacy of 20% subcutaneous immunoglobulin (Ig20Gly) administered weekly or every 2 weeks in Japanese patients with primary immunodeficiency diseases: a phase 3, open-label study
在日本原发性免疫缺陷病患者中，每周或每两周皮下注射20%免疫球蛋白（Ig20Gly）的药代动力学、安全性和有效性：一项3期开放标签研究
期刊:Immunotherapy Advances
影响因子:4.9
doi:10.1093/immadv/ltae001
Kanegane, Hirokazu; Endo, Akifumi; Okada, Satoshi; Ohnishi, Hidenori; Ishimura, Masataka; Nishikomori, Ryuta; Imai, Kohsuke; Nonoyama, Shigeaki; Muramatsu, Hideki; Wada, Taizo; Kuga, Atsushi; Sakamoto, Ko; Russo-Schwarzbaum, Sharon; Chu, Liang-Hui; McCoy, Barbara; Li, Zhaoyang; Yel, Leman
